Effects of valsartan, benazepril and their combination in overt nephropathy of type 2 diabetes: A prospective, randomized, controlled trial — Piero Ruggenenti (2019) | RDL Network
Effects of valsartan, benazepril and their combination in overt nephropathy of type 2 diabetes: A prospective, randomized, controlled trial
Article 2019 en
Authors
PR
Piero Ruggenenti
MT
Matias Trillini
DB
Draženka Pongrac Barlovič
Abstract
1 min read
In people with type 2 diabetes with nephropathy, valsartan (320 mg/d) safely postponed ESRD more effectively than benazepril (20 mg/d) or than halved doses of both medications.
Norman K. Hollenberg, Hans‐Henrik Parving, Giancarlo Viberti, Giuseppe Remuzzi, Susan Y. Ritter, Steven L. Zelenkofske, Albert Kandra, William Daley, Ricardo Rocha
William F. Keane, Zhongxin Zhang, Paulette A. Lyle, Mark E. Cooper, Dick de Zeeuw, Jean-Pierre Grunfeld, James P. Lash, Janet B. McGill, William E. Mitch, Giuseppe Remuzzi, Shahnaz Shahinfar, Steven Snapinn, Robert D. Toto, Barry M. Brenner
.webp){kind=small}
Discussion(0)
No comments yet. Be the first to comment.